Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Efficacy And Safety Of Neoadjuvant Chemotherapy With Concurrent Liposomal-encapsulated Doxorubicin, Paclitaxel And Trastuzumab For Human Epidermal Growth Factor Receptor 2-positive Breast Cancer In Clinical Practice
J. Gavilá, Á. Guerrero, M. A. Climent, A. Fernández, F. Gozalbo, M. Carrascosa, J. Camps, V. Guillém, A. Ruiz
Published 2014 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
AbstractBackground Based on previous results obtained with non-pegylated liposomal-encapsulated doxorubicin (TLC-D99) together with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer (BC), a similar regimen was evaluated in the neoadjuvant setting in a prospectively selected series of consecutive patients with clinical stage II–III BC. Primary and secondary objectives included the rate of pathologic complete response (pCR), safety, and predictive factors of pCR.MethodsPatients received six cycles of TLC-D99 (50 mg/m2 every 3 weeks), paclitaxel (80 mg/m2 weekly) and trastuzumab (4 mg/kg initial dose and 2 mg/kg weekly). All patients underwent surgery after treatment. pCR was defined as the absence of invasive cancer cells in the breast and the axilla.ResultsSixty-two patients with a median age of 46.6 years were analyzed. Stage IIIA was diagnosed in 43.5 % of patients and 14.5 % had inflammatory BC. Conservative surgery was performed in 46.8 % of the patients and pCR was achieved in 63 % (95 % CI 50.5–75.5). Patients with estrogen receptor (ER)-negative tumors presented a significantly higher pCR rate than patients with ER-positive tumors (74.4 vs 43.5 %; P = 0.028). Forty-five patients (72.6 %) completed study treatment and 80.6 % received at least five treatment cycles. No patients developed congestive heart failure and 14.5 % of patients showed a ≥10 % decrease in the left ventricular ejection fraction.ConclusionThe triple combination therapy assessed is effective and safe, offering a high pCR rate in patients with HER2-positive BC.
This paper references
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
B. Fisher (1998)
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
M. Untch (2012)
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
R. Rouzier (2005)
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
V. Guarneri (2006)
Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99) given intraperitoneally to dogs.
P. Kanter (1994)
S5-6: Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA).
A. Schneeweiss (2011)
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.
H. Burstein (2003)
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
J. Thigpen (2012)
Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
B. Coudert (2007)
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.
D. B. Agus (2005)
Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study.
A. Antón (2011)
Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
E. Fisher (2002)
Phase II trial of neoad - juvant pegylated liposomal doxorubicin with paclitaxel and trastuzumab in patients with operable Her - 2 - positive breast can
D Hyams (2009)
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
M. Untch (2004)
[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].
H. Watanabe (2009)
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.
B. Coudert (2006)
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
A. Buzdar (2005)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
L. Gianni (2012)
Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study
J. Cortés (2009)
Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.
B. Fisher (1997)
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
P. Rastogi (2008)
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
G. Batist (2001)
Pathobiology of preoperative chemotherapy
E. Fisher (2002)
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
M. Untch (2011)
[Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy].
H. Sinn (1994)
Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs.
P. M. Kanter (1993)
Inflammatory Breast Cancer: Pilot Study of Intensive Induction Chemotherapy (FEC‐HD) Results in a High Histologic Response Rate
B. Chevallier (1993)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
J. Baselga (2012)
Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 status.
L. Fernández-Morales (2007)
A phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen
Am Storniolo (2005)
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.
J. Baselga (2010)
Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
M. Tanioka (2010)
A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.
K. Ogston (2003)
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
H. Bear (2006)
Weekly paclitaxel in the treatment of recurrent ovarian cancer
R. Baird (2010)
Histologische Regression des Mammakarzinoms nach primärer (neoadjuvanter) Chemotherapie
H. Sinn (1994)
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
W. Xia (2005)
Phase II Trial of Neoadjuvant Pegylated Liposomal Doxorubicin with Paclitaxel and Trastuzumab in Patients with Operable Her2-Positive Breast Cancer.
D. Hyams (2009)
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
L. Gianni (2010)
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
J. A. van der Hage (2001)
The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells
R. Nahta (2004)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
D. B. Agus (2002)
lysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor , progesterone receptor , and HER 2 status
LA Fernandez-Morales (2007)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab
C. Adams (2005)
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
H. Burris (2005)
Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis
A. Seidman (2006)
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma
L. Harris (2002)
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
G. von Minckwitz (2008)
Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome.
D. Sataloff (1995)
Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety.
G. Lazaridis (2008)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
M. Piccart-Gebhart (2005)
HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
K. Pritchard (2006)
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
H. Kuerer (1999)
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
M. Pegram (1999)
Pharmacokinetics of HER2-targeted rhuMAb 2C4 (pertuzumab) in patients with advanced solid malignancies: phase Ia results
DE Allison (2003)
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
L. Gianni (2011)
Preoperative chemotherapy in operable breast cancer
G. Bonadonna (1993)
Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings
W. Yang (2007)
Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy
L. Gianni (2005)
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
M. Untch (2010)
TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer.
J. Chang (2011)
HER-2 and topoisomerase II as predictors of response to chemotherapy.
K. Pritchard (2008)
Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy.
K. Huber (2009)
EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors of response.
N. Spector (2006)
This paper is referenced by
Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer
Moisés Uriarte-Pinto (2016)
Significantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials
Y. Wu (2018)
Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis
Y. Wu (2018)
Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice
M. Zhao (2017)
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
J. Gavilá (2019)
Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution
S. Antolín (2019)